Lexicon Pharma (LXRX) to Present LX1031 Phase 2 Results at GASTRO 2009
More News related to LXRX
- Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
- Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
- Skymark Research Initiates Independent Research Coverage on Lexicon Pharmaceuticals, Inc.
- Unusual 11 Mid-Day Movers 01/20: DEAR, TIBB, DIET, PONE Higher; WAVX, CADC, AXU, STEC Lower
- Morning Movers 01/20: DEAR, TIBB, LXRX, CTZN, PONE, CREE Higher; VRS, NEXM, AXU, SUPX Lower
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."
The GASTRO 2009 meeting is a joint world conference in the area of gastroenterology. This meeting will bring together the world's leading organizations - the United European Gastroenterology Federation (UEGF), World Gastroenterology Organization (WGO), World Organization of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG) - for one of the biggest congresses in this area of medicine with more than 12,000 scientists from around the world expected to attend.
Related Categories
Corporate NewsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
